Daiichi Sankyo And AstraZeneca Launch Three Phase 3 Trials For Datopotamab Deruxtecan-Based Combinations In Advanced Nonsquamous NSCLC; TROPION-Lung10, Lung14, And Lung15 Studies Target High PD-L1 Expression And EGFR Mutations With First Patients Dosed
Portfolio Pulse from Benzinga Newsdesk
Daiichi Sankyo and AstraZeneca have initiated three Phase 3 trials for Datopotamab Deruxtecan-based combinations in advanced nonsquamous NSCLC. The studies, named TROPION-Lung10, Lung14, and Lung15, focus on high PD-L1 expression and EGFR mutations, with the first patients already dosed.
October 30, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca, in partnership with Daiichi Sankyo, has launched three Phase 3 trials for Datopotamab Deruxtecan in advanced nonsquamous NSCLC, targeting high PD-L1 expression and EGFR mutations.
The initiation of Phase 3 trials is a significant step in drug development, indicating potential future revenue streams if successful. The focus on high PD-L1 expression and EGFR mutations targets a specific patient group, which could lead to a competitive advantage in the NSCLC treatment market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80